Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 16, 2019Diabetes Technology & TherapeuticsOpen Access

Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRozalina G. McCoyHDHayley J. DykhoffLSLindsey R. Sangaralingham

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

McCoy et al. (2019) studied this question.

synapsesocial.com/papers/6a0fefa8b6f5ee0401601dadhttps://doi.org/10.1089/dia.2019.0213
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Automated Detection and Classification of Type 1 Versus Type 2 Diabetes Using Electronic Health Record Data2012 · 225 citations
  2. 2Adoption of new drugs by physicians: a survival analysis2012 · 50 citations
  3. 3Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2018 · 3,565 citations
  4. 4Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,293 citations
  5. 5Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs2003 · 137 citations